Literature DB >> 12841567

Central retinal vein occlusion risk profile: a case-control study.

M L Shahsuvaryan1, A K Melkonyan.   

Abstract

PURPOSE: To identify risk factors for central retinal vein occlusion (CRVO).
METHODS: This clinic-based case-control study included 408 patients with CRVO aged 21 years and older and 566 controls who were seen between January 1, 1990, and December 31, 2001. Multivariate logistic regression analysis was used to adjust for various factors and test potential interactions between the different variables.
RESULTS: An increased risk of CRVO was found in persons with systemic hypertension, but odds ratios were greater for older patients. Risk of CRVO increases with age and also in association with hypercoagulability. Diabetes mellitus, kidney disease, and glaucoma were associated with increased risk for CRVO. A significantly greater prevalence of higher erythrocyte sedimentation rate was present in young adults compared with older patients.
CONCLUSIONS: The results suggest a relationship between CRVO and certain risk factors (systemic hypertension, diabetes mellitus, kidney disease, glaucoma, older age) and support the possibility of an association between CRVO and urban location. The findings also support the potential value of medical treatment of underlying medical conditions in preventing occurrence of CRVO.

Entities:  

Mesh:

Year:  2003        PMID: 12841567     DOI: 10.1177/112067210301300505

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  13 in total

Review 1.  Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion.

Authors:  Tasanee Braithwaite; Afshan A Nanji; Paul B Greenberg
Journal:  Cochrane Database Syst Rev       Date:  2010-10-06

2.  Therapeutic potential of intravitreal pharmacotherapy in retinal vein occlusion.

Authors:  Marianne L Shahsuvaryan
Journal:  Int J Ophthalmol       Date:  2012-12-18       Impact factor: 1.779

Review 3.  Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion.

Authors:  Tasanee Braithwaite; Afshan A Nanji; Kristina Lindsley; Paul B Greenberg
Journal:  Cochrane Database Syst Rev       Date:  2014-05-01

4.  Similarities and differences in systemic risk factors for retinal artery occlusion and retinal vein occlusion: A nationwide case-control study.

Authors:  Marie Ørskov; Henrik Vorum; Torben Bjerregaard Larsen; Gregory Y H Lip; Toke Bek; Flemming Skjøth
Journal:  Int Ophthalmol       Date:  2022-09-02       Impact factor: 2.029

5.  Influence of diabetes and diabetes type on anatomic and visual outcomes following central rein vein occlusion.

Authors:  J G Santiago; S Walia; J K Sun; J D Cavallerano; Z A Haddad; L P Aiello; P S Silva
Journal:  Eye (Lond)       Date:  2014-02-14       Impact factor: 3.775

6.  Twelve-month experience with Ozurdex for the treatment of macular edema associated with retinal vein occlusion.

Authors:  W J Mayer; A Wolf; M Kernt; D Kook; A Kampik; M Ulbig; C Haritoglou
Journal:  Eye (Lond)       Date:  2013-04-19       Impact factor: 3.775

7.  A longitudinal analysis of risk factors associated with central retinal vein occlusion.

Authors:  Maxwell S Stem; Nidhi Talwar; Grant M Comer; Joshua D Stein
Journal:  Ophthalmology       Date:  2012-11-20       Impact factor: 12.079

8.  The incidence of retinal vein occlusion in the ocular hypertension treatment study.

Authors:  Edward M Barnett; Aldo Fantin; Bradley S Wilson; Michael A Kass; Mae O Gordon
Journal:  Ophthalmology       Date:  2010-01-19       Impact factor: 12.079

Review 9.  Ocular associations of diabetes other than diabetic retinopathy.

Authors:  V Swetha E Jeganathan; Jie Jin Wang; Tien Yin Wong
Journal:  Diabetes Care       Date:  2008-09       Impact factor: 19.112

10.  The clinical relevance of ultra-widefield angiography findings in patients with central retinal vein occlusion and macular oedema receiving anti-VEGF therapy.

Authors:  Luke Nicholson; Clara Vazquez-Alfageme; Piyali Sen; Namritha V Patrao; Tunde Peto; Yit Yang; Sobha Sivaprasad; Philip G Hykin
Journal:  Eye (Lond)       Date:  2021-05-25       Impact factor: 4.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.